Abstract: Disclosed are popping pharmaceutical compositions, which comprise OTC or prescription drug, and popping material. The popping material includes pressurized gas trapped within cavities of a pharmaceutically acceptable material in a manner that allows the gas to escape from the pharmaceutical composition upon dissolution, contact with saliva or shattering of the popping material. Such an oral pharmaceutical composition may be popular with children that will prefer it on other ones, which do not pop. Methods for preparation of such oral pharmaceutical compositions are also disclosed.

Abstract: Various compounds can be administered orally to humans or animals for the purpose of enhancing nitric oxide production. Enhancing nitric oxide production is beneficial for those looking to increase lean body mass or enhance exercise performance. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. L-Arginine and alpha amino n-Butryate work synergistically to enhance nitric oxide production and may further be coupled with either and/or a) an inhibitor of nitric oxide breakdown or b) a nitric oxide potentiators or other precursor and serve to accomplish this goal of enhance nitric oxide. The composition may be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.

Abstract: Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.

Abstract: Provided are oral compositions and devices comprising an active agent that is one of chlorine dioxide-generating components, a chlorine dioxide-containing solution, and combinations thereof.

Abstract: The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.

Abstract: A method of dosing pharmaceutically active ingredients in a compressed chewing gum tablet includes the steps of: providing one or more pharmaceutically active ingredients, mixing a chewing gum composition including the one or more pharmaceutically active ingredients and chewing gum granules, the chewing gum granules including gum base, and dosing the chewing gum composition to obtain a desired weight of the chewing gum composition and thereby obtaining a desired dose of the pharmaceutically active ingredient in the chewing gum tablet.

Abstract: The present invention provides stable medicament-containing chewing gum compositions comprising an inclusion complex comprising cyclodextrin and one or more active compound(s) according to formula I, such as cetirizine, and methods for preparing such chewing gum.

Abstract: The present disclosure describes novel carbon-based diazeniumdiolates agents and compounds or salts or prodrugs thereof that release nitric oxide for the treatment of neuropathic gastrointestinal dysfunction. The neuropathic gastrointestinal dysfunction refers to disorders associated with motility, sensation and neuromuscular function that include but are not limited to conditions such as delayed gastric emptying.

Abstract: A compressed chewing gum tablet includes at least a first and a second chewing gum module, the first chewing gum module including a first chewing gum composition including at least a first active ingredient and chewing gum granules containing gum base, the second chewing gum module including a second chewing gum composition including at least a second active ingredient and chewing gum granules containing gum base, wherein the first active ingredient is a pharmaceutically active ingredient, and the second active ingredient is selected from the group consisting of pharmaceutically active ingredients and enhancers, wherein the gum base content of the first and second chewing gum modules is different.

Abstract: A compressed chewing gum tablet includes one or more pharmaceutically active ingredients and one or more enhancers, wherein the chewing gum tablet includes at least one chewing gum module including a chewing gum composition, and wherein the chewing gum composition includes chewing gum granules containing gum base, and wherein the enhancers are at least partly contained within at least a part of the chewing gum granules.

Abstract: A multi portion intra-oral dosage form has at least one pharmaceutically active agent or health promoting agent with at least one portion comprises a component for creating a noticeable organoleptic sensation. The sensory markers or signals are conceptual aids for a subject using the dosage form where the organoleptic sensation is such that it facilitates the subject to identify a portion and differentiate between different portions. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N?-oxide, nomicotine, (S)-nicotine-N-?-glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.

Abstract: The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms.

Abstract: The present invention relates to compressed chewing gum tablets comprising a useful antihistamine. In particular, the present invention is directed to compressed chewing gum tablet, which effectively mask the unpleasant tastes of compound according to formula I, such as cetirizine, contained therein and methods for preparing such compressed chewing gum tablet.

Abstract: Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.

Abstract: The present invention provides a method for providing a coating comprising maltitol which can prevent the coating from being chipped without using reinforcement or binder at low cost and at short times. The present invention provides a method for providing a coating for a core material, which comprises: (i) a first coating step which comprises coating the core material with an aqueous solution comprising maltitol and a crystallization inhibitor which inhibits crystallization of maltitol in an amount more than 3% by weight and not more than 6% by weight based on the weight of total solid content of sugar alcohols including maltitol in the solution, (ii) a second coating step which comprises coating the core material which has been coated by the first coating step with a powder maltitol composition, and (iii) a drying step which comprises drying the thus coated core material.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

Abstract: A center-filled chewing gum product includes functional agents and a chewing gum substance enclosing a center-filling, wherein the center-filling includes toothpaste and the functional agents include at least one anti-plaque agent.

Abstract: An object of the invention is to provide a chewing composition containing Coenzyme Q10 with improved release properties in the oral cavity. Another object is to provide a process for improving the release properties of Coenzyme Q10 in the oral cavity. Coenzyme Q10 is encapsulated in cyclodextrin, and the resulting inclusion complex is used as a Coenzyme Q10 component. The content of Coenzyme Q10 in the inclusion complex is preferably low. It is preferably 40 wt % or less, and more preferably 20 wt %.

Abstract: A composition in the form of a chewing gum composition or a confectionery composition containing an encapsulated stain removing agent selected from anionic and non-ionic surfactants and methods of preparing and using the same to remove stains from dental material including teeth.

Abstract: A method for the production fentanyl-based analgesics for their oral transmucosal administration in a candy-like dosage form, involving the dissolution of a pharmacologically accepted amount of Fentanyl citrate in purified water and the dissolution of a pharmacologically accepted dye in purified water. Mix polyalcohol sugar with purified water with a ratio polyalcohol/sugar between 17 and 19.5% by weight. Stir slowly over low heat until a liquid and smooth mass is obtained. Add sucrose to this liquid mass with a ratio liquid mass/sucrose between 65% and 67.5% by weight. Heat the mass and bring to a boil from an initial temperature of 128°-1320 C to a maximum temperature of 148°-152° C., until its water content evaporates and the weight of the mass obtained in this step reaches between 88% and 90% by weight with respect to the initial total weight of the liquid mass.

Abstract: A composition in the form of a chewing gum composition or a confectionery composition containing a stain removing complex of a stain removing agent and a cyclodextrin compound and methods of preparing and using the same to remove stains from dental material including teeth.

Abstract: The present invention provides for compositions and methods for accelerating the rate of delivery of lofexidine to the systemic circulation by transmucosal administration through the nasal, sublingual, or buccal routes to provide rapid response in the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine, to a patient in need of such treatment. Compositions of lofexidine formulated for transmucosal delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods utilize lofexidine compositions formulated for transmucosal delivery through nasal, sublingual, or buccal routes of administration in an amount effective for the treatment of the drug indications.

Abstract: The present invention is a dissolvable candy which provides effective tongue scraping action. The candy is a soft pliable edible dissolvable candy material, such as a GUMMI-BEAR type confection, having a generally oval shape. A plurality of segments are formed with hard candy in one surface of the soft candy. Preferably, the segments have raised ridges which are suitable for abrading the tongue. A blister have a freshening agent is formed on the same side as the hard candy segments. A plurality of depressions are formed in another side of the soft candy to facilitate adhering the soft candy to the roof of the mouth.

Abstract: The invention provides co-agglomerates of sucralose and a polyol, wherein the co-agglomerate comprises grains of polyol onto which sucralose has been dried, as well as methods for making such co-agglomerates. In general, the methods comprise contacting a dry powder of polyol with a liquid solution of sucralose in a food acceptable solvent under conditions which moisten, but not dissolve the polyol powder, to form a moist mixture, and drying the moist mixture to form a co-agglomerate comprising grains of agglomerated polyol onto which sucralose has been dried. Also provided are artificial sweetener carriers comprising bentonite which comprise sucralose. The invention features pharmaceutical, cosmetic, and food compositions, especially chewing gum, comprising a co-agglomerate of the invention, comprising a bentonite carrier, or comprising both.

Abstract: A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and/or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.

Abstract: The invention provides a method for the prevention and/or activation of defense mechanisms in the human body against conditions, disorders or diseases relating to the presence of free radicals, such as; environmental pollution, aging or smoking by rising the administration to a mammal, namely a human being, of an effective amount of a phytonutrient-and-citric-based edible dosage, during or after tobacco consumption and which is intended to prevent pathologies, conditions, disorders or diseases relating to the presence of free radicals in the human body. Likewise, the therapeutic method of the invention enables activation of defense mechanisms in the human body to reduce conditions, disorders or diseases relating to the presence of free radicals in the body.

Abstract: A package assembly for supporting a delivery system for inclusion in an edible composition is disclosed. The edible composition is formulated to have at least one ingredient encapsulated with an encapsulating material. The delivery system and the resulting edible composition may include other ingredients to create a desired release profile for the at least one ingredient, any of which can be indicated by indicia on the assembly.

Abstract: The present invention relates to a confectionery composition including a confectionery region and a marking on the exterior surface of the region, where the marking includes at least one active agent. A method of manufacturing the confectionery composition and of delivering an active agent using the confectionery composition is also provided.

Abstract: The invention relates to biologically active nanoparticles of a carbonate-substituted non-stoichiometric hydroxyapatite, having: a) a crystallinity degree CD lower than 40%, the crystallinity degree being defined as CD=(1?X/Y)·100 wherein: Y=height of the diffraction maximum at 2?=33°, X=height of the diffraction background at 2?=33° of the nanoparticles X-ray diffraction pattern; b) a length L ranging from 20 to 200 nm and a width W ranging from 5 to 30 nm; and c) an aspect ratio AR comprised between 2 and 40, the aspect ratio being defined as AR=L/W. The biologically active nanoparticles of the invention find a preferred use in oral or dental hygiene applications and may be formulated as compositions for oral or dental hygiene such as, for example, solutions, suspensions, oils, gels or other solid products.

Abstract: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.

Abstract: The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C.

Abstract: The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms.

Abstract: A method of preventing biofilm formation in an environment including the steps of administering to the environment an effective amount of a peptide having the amino acid sequence NH2-lys-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1] The method is useful in preventing the formation of biofilms in various environments including a home, workplace, laboratory, industrial environment, aquatic environment, animal body or human body. A method of inhibiting the growth of oral microorganisms including the steps of administering to an oral environment an effective amount of a peptide having the amino acid sequence NH2-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1].

Abstract: Blast Induced Traumatic Brain Injury or bTBI needs objective and subjective testing that can be made quickly in the field. Subjective tests using shapes, textures, tastes and odors as disposable, edible candies on a stick may be carried in a field kit. An objective test that employs a similar candy on a stick bearing antibodies bound to bioluminescent marker reads whether molecules believed to be released into the mouth from an injured brain are present if they bind to the specific antibody which may then be read.

Abstract: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.

Abstract: Stain-removing oral compositions, such as gum compositions are herein provided. The compositions include a chelating agent and a surfactant. The surfactant includes a fatty acid salt and at least one component selected from nonionic and anionic surfactants. The fatty acid salt may have at least one hydroxyl functionality. The oral compositions may optionally include an abrasive agent.

Abstract: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use.

Abstract: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use.

Abstract: The present invention relates to a dosage form including both a disintegrative tablet portion and a hard candy portion, wherein: (i) the disintegrative tablet portion comprises at least one pharmaceutically active agent, and (ii) the hard candy portion covers at least 20% of the surface of the disintegrative tablet portion, and wherein the disintegration time of the hard candy portion is at least ten times longer than the disintegration time of the disintegrative tablet portion.

Abstract: Coated oral dosage forms for the delivery of nicotine in any form to a subject by rapid intraoral delivery of nicotine comprising at least one core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additives, wherein said at last one coating layer is buffered, whereby is used at least one amino acid as buffering agent. Also contemplated are a method for the delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as a method for producing said coated product and use of the same for obtaining a rapid intraoral uptake of nicotine.

Abstract: A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least one amino acid, preferably at least one endogenous amino acid. Also contemplated is a method for the oral delivery of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as methods for manufacturing the oral formulation, the use of said oral formulation for obtaining transmucosal uptake of nicotine in the oral cavity of a subject, and use of nicotine for the production of an oral formulation as per above for the treatment of a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.

Abstract: A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution's components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution include: specially denatured alcohol (SDA); Triton x-100; sodium saccharin; 1,8 cineole (eucalyptol); thymol; methyl salicylate; menthol; sorbitol and/or glycerin; sodium benzoate; poloxamer 407; polysorbate 80; and distilled water. Optionally, the solution also includes one or more of the following: citric acid; sambucus nigra agglutinin; a lectin that binds 2,3 sialic acid; nonoxynol-9; sialyllactose; a protease; a protease inhibitor; and/or chloroquine. The solution is applied to the nasal cavity via a pre-moistened cotton swab or a pre-moistened facial tissue and the solution is applied to the back of the throat via a spray, gum, or gargle solution.

Abstract: The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the amount of a weak base, thereby increasing the stability of compositions such as chewing gum compositions and raising the pH of saliva to a pH greater than about 7.5 to facilitate the substantially complete conversion of pilocarpine from its ionized to its un-ionized form. Methods for using the compositions of the present invention for treating conditions such as dry mouth are also provided.

Abstract: This invention provides substantially spherical, micron and submicron sized alkali metal bicarbonate particles. When combined with a liquid medium, the alkali metal bicarbonate particles have an exceptional capability to form a flowable slurry which demonstrates long term stability.

Abstract: The present invention relates to oral delivery systems, such as confectionery and chewing gum compositions, and methods for imparting the perception of nasal clearing to a user. In particular, the present invention includes confectionery and chewing gum compositions including a compound selected from 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 3-butenyl isothiocyanate, 3-methylthiopropyl isothiocyanate, and any combinations thereof and methods. The delivery systems promote the perception of nasal clearing in the user.

Abstract: The invention provides a body weight gain inhibitor, a fat amount gain inhibitor, a medicament for prevention and/or treatment of obesity, a food composition having inhibitory effect on body weight gain and a food composition having inhibitory effect on fat amount gain, each containing ?-polylysine or a salt thereof. In another aspect of the invention, the described compositions are useful for inhibiting body weight gain, inhibiting fat amount gain and preventing and/or treating obesity.

Abstract: Moisture of the skin, skin lipid balance and skin smoothness can be improved by administering an oral composition containing, as active ingredients, proteins and/or protein hydrolysates wherein the total proteins and hydrolysates contain at least 2 wt. % of cysteine residues. Preferably, the hydrolysates have an average molecular weight of between 200 and 4000 Dalton. The composition is administered in such an amount that between 25 and 500 mg of cysteine per day is supplied.

Abstract: Acyclic compounds containing an ether functionality external to the ring can be used as rhinologically active substances. In the regions of the mouth, the throat and the airways they produce a refreshing and clearing feeling.

Abstract: A chewing gum possessing tooth cleaning effects, which chewing gum includes at least gum base and: a) at least one active cosmetic ingredient selected from whitening agents, b) at least one active cosmetic ingredient selected from fresh-breath agents, c) at least one active therapeutic ingredient selected from anti-plaque agents, d) at least one active therapeutic ingredient selected from anti-gingivitis agents. The chewing gum is intended for round the year daily use as the major tooth cleaning agent.